Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
Status:
Terminated
Trial end date:
2019-08-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the efficacy and safety of everolimus administered as
a first-line treatment in newly-diagnosed patients with advanced or inoperable
Gastrointestinal (GI) or pancreatic neuroendocrine tumors.